LINVESTA EMP 25/5MG Tablet

LINVESTA EMP 25/5MG Tablet is a pharmaceutical formulation that combines two different drugs, Linagliptin & Empagliflozin, in a single tablet. It is likely prescribed for the management of certain medical conditions, particularly related to diabetes.

Active Ingredients:

1. Linagliptin: This is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It works by increasing the levels of incretin hormones, which in turn stimulate the release of insulin and reduce the amount of glucose produced by the liver.
2. Empagliflozin: This is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. It works by preventing the reabsorption of glucose by the kidneys, leading to increased glucose excretion in the urine.

Uses:

LINVESTA EMP 25/5MG Tablet is commonly prescribed for the treatment of type 2 diabetes mellitus. The combination of Linagliptin and Empagliflozin helps control blood sugar levels through different mechanisms, providing a complementary approach to managing diabetes.

Side Effects:

As with any medication, LINVESTA EMP 25/5MG Tablet may cause side effects. Common side effects associated with Linagliptin and Empagliflozin include:

1. Hypoglycemia (low blood sugar): Especially when used in combination with other antidiabetic medications.
2. Genital and urinary tract infections: More commonly associated with SGLT2 inhibitors like Empagliflozin.
3. Increased urination: Due to the mechanism of action of SGLT2 inhibitors.
4. Upper respiratory tract infections: Some individuals may experience respiratory infections.
5. Increased thirst: A possible side effect due to increased glucose excretion.

It’s important to report any unusual or severe side effects to your healthcare provider.

When Not to Use:

LINVESTA EMP 25/5MG Tablet may not be suitable for everyone. It should be avoided or used with caution in certain situations:

1. Hypersensitivity: If you are allergic to Linagliptin, Empagliflozin, or any other components of the medication.
2. Severe renal impairment: In individuals with severe kidney problems, the use of SGLT2 inhibitors like Empagliflozin may need to be adjusted or avoided.
3. Type 1 diabetes: This medication is specifically for type 2 diabetes and should not be used in individuals with type 1 diabetes.
4. Pregnancy and breastfeeding: The safety of this medication during pregnancy and breastfeeding should be discussed with a healthcare professional.

Always follow the guidance of your healthcare provider and inform them of any pre-existing medical conditions or medications you are taking before starting LINVESTA EMP 25/5MG Tablet.